South Korea, Taiwan Approve Cubicin for Bloodstream Infections

Cubist Pharmaceuticals announced that Cubicin received approvals for treating S. aureus bacteremia, including right-sided infective endocarditis (SAB/RIE), in both South Korea and Taiwan.

Cubist said the recent approval in South Korea includes both complicated skin and skin structure infections (cSSSI) and SAB/RIE.

According to the company, Cubicin (daptomycin for injection) was previously approved in Taiwan for cSSSI caused by Gram-positive bacteria.

The approvals were received by Kuhnil Pharmaceutical, Cubicin marketing partner for South Korea, and TTY BioPharm, Cubicin marketing partner for Taiwan, the company added.